Investigation of Plasma Proteins in Patients With Hereditary Haemorrhagic Telangiectasia and PAVMs

This study is currently recruiting participants.

Verified by Imperial College London, August 2008

First Received: September 29, 2005 Last Updated: August 12, 2008 History of Changes

Sponsored by:	Imperial College London
Information provided by:	Imperial College London
ClinicalTrials.gov Identifier:	NCT00230672

Purpose

Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an disease that leads to the development of dilated and fragile blood vessels, including arteriovenous malformations in the lungs (PAVMs). We hypothesize that the genetically-determined abnormality in the blood vessels of HHT patients leads to alteration in the concentrations or activity of several proteins in the blood stream. We propose to take blood samples from patients at defined times in order to study changes in blood protein levels and activity

Condition
Telangiectasia, Hereditary Hemorrhagic

Genetics Home Reference related topics: hemophilia hereditary hemorrhagic telangiectasia

MedlinePlus related topics: Arteriovenous Malformations

U.S. FDA Resources

Study Type:	Observational
Study Design:	Prospective
Official Title:	Studies of Plasma Proteins Derived From Pulmonary Arteriovenous Malformation Patients

Further study details as provided by Imperial College London:

Estimated Enrollment:	70
Study Start Date:	March 2005

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:Patients with hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations -

Exclusion Criteria:Unable to provide informed consent

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00230672

Contacts

Contact: Claire Shovlin

0208 383 1000

c.shovlin@imperial.ac.uk

Locations

United Kingdom
Imperial College Hammersmith Campus	Recruiting
London, United Kingdom, W12 0NN
Contact: Claire Shovlin 0208 383 1000 c.shovlin@imperial.ac.uk

Sponsors and Collaborators

Imperial College London

Investigators

Principal Investigator:

Claire Shovlin

Imperial College London

More Information

No publications provided

Study ID Numbers:	IC/CLS7
Study First Received:	September 29, 2005
Last Updated:	August 12, 2008
ClinicalTrials.gov Identifier:	NCT00230672 History of Changes
Health Authority:	United Kingdom: Research Ethics Committee

Study placed in the following topic categories:

Pulmonary Arteriovenous Malformation
Cardiovascular Abnormalities
Telangiectasia, Hereditary Hemorrhagic
Hematologic Diseases
Blood Coagulation Disorders
Vascular Diseases
Hemostatic Disorders

Hemorrhagic Disorders
Telangiectasis
Vascular Malformations
Arteriovenous Malformations
Hereditary Hemorrhagic Telangiectasia
Congenital Abnormalities

Additional relevant MeSH terms:

Hemorrhagic Disorders
Cardiovascular Abnormalities
Hematologic Diseases
Telangiectasia, Hereditary Hemorrhagic
Vascular Malformations
Telangiectasis

Vascular Diseases
Cardiovascular Diseases
Arteriovenous Malformations
Hemostatic Disorders
Congenital Abnormalities

ClinicalTrials.gov processed this record on May 07, 2009